Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease Pharmaceutical Investing
New Data from the AEROSURF® Phase 2b Clinical Program shows AEROSURF® Appears to Reduce Incidence and Severity of Bronchopulmonary Dysplasia in Preterm Infants with RDS Biotech Investing
Life Science Big News Roundup: BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate; Kalytera Announces Additional Share Issuance for Services under Payments Agreement with Salzman Group Life Science Investing
Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering Pharmaceutical Investing
SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data Pharmaceutical Investing
Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan Pharmaceutical Investing
